JP2016501208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501208A5 JP2016501208A5 JP2015544453A JP2015544453A JP2016501208A5 JP 2016501208 A5 JP2016501208 A5 JP 2016501208A5 JP 2015544453 A JP2015544453 A JP 2015544453A JP 2015544453 A JP2015544453 A JP 2015544453A JP 2016501208 A5 JP2016501208 A5 JP 2016501208A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- effective amount
- during
- treatment cycle
- surface area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 5
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 5
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 5
- 229960000684 cytarabine Drugs 0.000 claims 5
- 229960000390 fludarabine Drugs 0.000 claims 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 5
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960003334 daunorubicin citrate Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 229940052372 daunorubicin citrate liposome Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195162 | 2012-11-30 | ||
| EP12195162.8 | 2012-11-30 | ||
| PCT/EP2013/074862 WO2014083058A1 (en) | 2012-11-30 | 2013-11-27 | Combination therapy with volasertib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501208A JP2016501208A (ja) | 2016-01-18 |
| JP2016501208A5 true JP2016501208A5 (enExample) | 2017-01-12 |
Family
ID=47325907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544453A Pending JP2016501208A (ja) | 2012-11-30 | 2013-11-27 | ボラセルチブとの併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140154304A1 (enExample) |
| EP (1) | EP2925343A1 (enExample) |
| JP (1) | JP2016501208A (enExample) |
| KR (1) | KR20150090091A (enExample) |
| CN (1) | CN104812400A (enExample) |
| AU (1) | AU2013351180A1 (enExample) |
| BR (1) | BR112015011748A2 (enExample) |
| CA (1) | CA2889787A1 (enExample) |
| CL (1) | CL2015001258A1 (enExample) |
| EA (1) | EA201500579A1 (enExample) |
| IL (1) | IL238174A0 (enExample) |
| IN (1) | IN2015DN03075A (enExample) |
| MX (1) | MX2015006592A (enExample) |
| PH (1) | PH12015501113A1 (enExample) |
| WO (1) | WO2014083058A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867831B2 (en) * | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| CN104306336B (zh) * | 2014-11-18 | 2016-08-24 | 河北天成药业股份有限公司 | 枸橼酸柔红霉素脂质体注射液的制备工艺 |
| US10927418B2 (en) * | 2015-11-11 | 2021-02-23 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| EP4157281A4 (en) * | 2020-05-27 | 2024-11-27 | Duke University | COMPOSITIONS AND METHODS FOR SENSITIZING ACUTE MYELOID LEUKEMIAS TO CHEMOTHERAPY |
| CN116785296B (zh) * | 2023-06-06 | 2025-09-05 | 河北渤腾医药技术有限公司 | 一种plk1的抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3876265B2 (ja) | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| AU2007334775A1 (en) * | 2006-12-20 | 2008-06-26 | Universitatsklinikum Hamburg-Eppendorf | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| PL3300601T3 (pl) * | 2007-02-16 | 2022-05-02 | Rotalec Ip Holdings Llc | Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
-
2013
- 2013-11-25 US US14/088,948 patent/US20140154304A1/en not_active Abandoned
- 2013-11-27 WO PCT/EP2013/074862 patent/WO2014083058A1/en not_active Ceased
- 2013-11-27 KR KR1020157014213A patent/KR20150090091A/ko not_active Withdrawn
- 2013-11-27 CN CN201380062203.7A patent/CN104812400A/zh active Pending
- 2013-11-27 AU AU2013351180A patent/AU2013351180A1/en not_active Abandoned
- 2013-11-27 EP EP13795533.2A patent/EP2925343A1/en not_active Withdrawn
- 2013-11-27 MX MX2015006592A patent/MX2015006592A/es unknown
- 2013-11-27 CA CA2889787A patent/CA2889787A1/en not_active Abandoned
- 2013-11-27 EA EA201500579A patent/EA201500579A1/ru unknown
- 2013-11-27 BR BR112015011748A patent/BR112015011748A2/pt not_active IP Right Cessation
- 2013-11-27 JP JP2015544453A patent/JP2016501208A/ja active Pending
-
2015
- 2015-04-12 IL IL238174A patent/IL238174A0/en unknown
- 2015-04-13 IN IN3075DEN2015 patent/IN2015DN03075A/en unknown
- 2015-05-11 CL CL2015001258A patent/CL2015001258A1/es unknown
- 2015-05-20 PH PH12015501113A patent/PH12015501113A1/en unknown
-
2017
- 2017-03-03 US US15/448,660 patent/US20170173023A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501208A5 (enExample) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2010285439A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2013522303A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (enExample) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| JP2012522841A5 (enExample) | ||
| JP2024516363A5 (enExample) | ||
| JP2024516795A5 (enExample) | ||
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2021532171A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| JP2021522246A5 (enExample) | ||
| JP2013540734A5 (enExample) | ||
| JP2017516842A5 (enExample) | ||
| JP2012526099A5 (enExample) |